Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer.
circulating microRNA
diagnostic performance
expression profile
pancreatic cancer
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
10
2019
accepted:
10
01
2020
entrez:
3
3
2020
pubmed:
3
3
2020
medline:
3
3
2020
Statut:
epublish
Résumé
The burden of pancreatic cancer (PanC) requires innovation in the current diagnostic approach. This study aimed to uncover new circulating microRNAs (miRNAs) that would distinguish patients with PanC from healthy subjects (HS) compared with the cancer antigen 19-9 (CA 19-9), and predict patients' clinical phenotypes and outcomes. MiRNA expression profiles in plasma were investigated by using a two-stage process. In a discovery phase, miRNAs levels were analyzed using the GeneChip™ miRNA 4.0 Affymetrix assay in 10 pools of plasma samples from PanC patients and HS; in a validation phase, significantly altered miRNAs were re-tested in independent cohorts of cancer patients and controls by droplet digital PCR (ddPCR). The diagnostic performance of the resulting miRNAs was compared to CA 19-9 determinations, and the associations of miRNAs plasma levels with patients' clinical phenotypes and outcomes were also taken into account. Bioinformatics selection of miRNAs differentially expressed in plasma uncovered miR-18a-5p, miR-122-5p, miR-1273g-3p, and miR-6126 as candidate oncogenic miRNAs in PanC. The ddPCR technology confirmed the significant over-expression of miR-122-5p, miR-1273g-3p, and miR-6126 in PanC compared to HS, in line with the trend of the CA 19-9 levels. Plasma levels of miR-1273g-3p, in combination with CA 19-9, showed higher power in distinguishing PanC patients from HS compared to the CA 19-9 tested alone, with a gain in both sensitivity and negative predictive value indicating a low false-negative rate (SE = 90.2% and NPV = 92.3% vs. SE = 82.1% and NPV = 87.9%). None of the oncogenic miRNAs were able to distinguish between a neoplastic and a proliferative/inflammatory disease of the pancreas, and were not able to stratify subjects according to the clinical risk for the disease. The only valuable association in PanC patients was found between miR-1273g-3p and tumor stage, and increased miR-122-5p levels emerged as independent negative prognostic factor for PanC patients (HR = 1.58, 95% CI = 1.03-2.43,
Identifiants
pubmed: 32117716
doi: 10.3389/fonc.2020.00044
pmc: PMC7010806
doi:
Types de publication
Journal Article
Langues
eng
Pagination
44Informations de copyright
Copyright © 2020 Mazza, Gioffreda, Fontana, Biagini, Carella, Palumbo, Maiello, Bazzocchi, Andriulli and Tavano.
Références
Int J Cancer. 2013 Nov 15;133(10):2392-7
pubmed: 23649606
Circulation. 2007 Feb 20;115(7):928-35
pubmed: 17309939
N Engl J Med. 2006 Dec 21;355(25):2615-7
pubmed: 17182986
Pancreas. 2012 Oct;41(7):1013-8
pubmed: 22513294
Lancet Oncol. 2009 Jan;10(1):88-95
pubmed: 19111249
Am J Epidemiol. 2004 May 1;159(9):882-90
pubmed: 15105181
Biomed Res Int. 2014;2014:620530
pubmed: 25243165
Sci Rep. 2018 Nov 6;8(1):16389
pubmed: 30401891
JAMA. 2014 Jan 22-29;311(4):392-404
pubmed: 24449318
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):445-53
pubmed: 22664588
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Gene. 2018 Oct 5;673:181-193
pubmed: 29913239
J Natl Cancer Inst. 2009 Mar 18;101(6):424-31
pubmed: 19276450
Pancreas. 2015 Jul;44(5):686-92
pubmed: 25938853
In Vivo. 2014 May-Jun;28(3):293-7
pubmed: 24815829
PLoS One. 2012;7(4):e34151
pubmed: 22511932
PLoS One. 2008 Sep 05;3(9):e3148
pubmed: 18773077
World J Gastroenterol. 2014 Aug 28;20(32):11182-98
pubmed: 25170203
Cent Eur J Immunol. 2018;43(3):314-324
pubmed: 30588176
Br J Cancer. 2013 Feb 5;108(2):361-9
pubmed: 23329235
Clin Cancer Res. 2013 Jul 1;19(13):3600-10
pubmed: 23697990
Int J Cancer. 2012 Aug 1;131(3):683-91
pubmed: 21913185
Oncotarget. 2015 Nov 24;6(37):40295-309
pubmed: 26516699
Clin Chem. 2012 Mar;58(3):610-8
pubmed: 22194634
Cancer Res. 2016 Dec 15;76(24):7194-7207
pubmed: 27742688
Clin Gastroenterol Hepatol. 2006 Nov;4(11):1366-72; quiz 1301
pubmed: 16945591
PLoS One. 2013 Dec 23;8(12):e82753
pubmed: 24376572
Pancreas. 2015 Jul;44(5):693-712
pubmed: 25931254
Mol Med Rep. 2018 Mar;17(3):4619-4626
pubmed: 29328379
Lancet. 2004 Mar 27;363(9414):1049-57
pubmed: 15051286
Mol Biol Rep. 2019 Aug;46(4):4175-4183
pubmed: 31123908
Br J Cancer. 2011 Nov 22;105(11):1733-40
pubmed: 22045190
Int J Oncol. 2015 Feb;46(2):539-47
pubmed: 25384963
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087